International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(8), P. 3572 - 3572
Published: April 10, 2025
Type 2 diabetes (T2D) and cardiovascular diseases (CVDs) are major public health challenges worldwide. Metabolomics, the exhaustive assessment of metabolites in biological systems, offers important insights regarding metabolic disturbances related to these disorders. Recent advances toward integration metabolomics into clinical practice facilitate discovery novel biomarkers that can improve diagnosis, prognosis, treatment T2D CVDs discussed this review. Metabolomics potential characterize key alterations associated with disease pathophysiology treatment. is a heterogeneous develops through diverse pathophysiological processes molecular mechanisms; therefore, disease-causing pathways not completely understood. studies have identified several robust clusters variants representing biologically meaningful, distinct pathways, such as beta cell proinsulin cluster pancreatic insulin secretion, obesity, lipodystrophy, liver/lipid cluster, glycemia, blood pressure, syndrome different causing resistance. Regarding CVDs, recent allowed metabolomic profile delineate contribute atherosclerosis heart failure, well development targeted therapy. This review also covers role integrated genomics other omics platforms better understand mechanisms, along transition precision medicine. further investigates use multi-metabolite modeling enhance risk prediction models for predicting first occurrence adverse events among individuals T2D, highlighting value approaches optimizing preventive therapeutic used practice.
Language: Английский